Nucleoside analogues exerting antiviral activity through a non-nucleoside mechanism

被引：18

作者：

De Clercq, E ^{[1
]}

机构：

[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium

来源：

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS | 2004年 / 23卷 / 1-2期

关键词：

neucloside analogues; HCMV; HIV;

D O I：

10.1081/NCN-120028339

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

In analogy with maribavir [1-(beta-L-ribofuranosyl)-isopropylamino-5,6-dichlorobenzimidazole], a nucleoside analogue that acts against human cytomegalovirus (HCMV) by a non-nucleoside mechanism, here I present three other examples of classes of nucleoside analogues (i.e. bicyclic furo[2,3-d]pyrimidine as well as HEPT and TSAO derivatives) that act against either HCMV or human immunodeficiency virus (HIV) through a non-nucleoside mode of action.

引用

页码：457 / 470

页数：14

共 56 条

[31] The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress [J].

Krosky, PM ;

Baek, MC ;

Coen, DM .

JOURNAL OF VIROLOGY, 2003, 77 (02) :905-914

[32] Resistance of human cytomegalovirus to benzimidazole ribonucleosides maps to two open reading frames: UL89 and UL56 [J].

Krosky, PM ;

Underwood, MR ;

Turk, SR ;

Feng, KWH ;

Jain, RK ;

Ptak, RG ;

Westerman, AC ;

Biron, KK ;

Townsend, LB ;

Drach, JC .

JOURNAL OF VIROLOGY, 1998, 72 (06) :4721-4728

[33] Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding [J].

Lalezari, JP ;

Aberg, JA ;

Wang, LH ;

Wire, MB ;

Miner, R ;

Snowden, W ;

Talarico, CL ;

Shaw, S ;

Jacobson, MA ;

Drew, WL .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (09) :2969-2976

[34] Synthesis of 3"-substituted TSAO derivatives with anti-HIV-1 and anti-HIV-2 activity through an efficient palladium-catalyzed cross-coupling approach [J].

Lobatón, E ;

Rodríguez-Barrios, F ;

Gago, F ;

Pérez-Pérez, MJ ;

De Clercq, E ;

Balzarini, J ;

Camarasa, MJ ;

Velázquez, S .

JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (18) :3934-3945

[35] 4"-H-TSAO-T, a novel prototype in the HIV-1 specific TSAO family [J].

Lobatón, E ;

Velázquez, S ;

San-Félix, A ;

De Clercq, E ;

Balzarini, J ;

Camarasa, MJ .

NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS, 2001, 20 (4-7) :711-714

[36] Dihydro(alkylthio)(naphthylmethyl)oxopyrimidines: Novel non-nucleoside reverse transcriptase inhibitors of the S-DABO series [J].

Mai, A ;

Artico, M ;

Sbardella, G ;

Quartarone, S ;

Massa, S ;

Loi, AG ;

DeMontis, A ;

Scintu, F ;

Putzolu, M ;

LaColla, P .

JOURNAL OF MEDICINAL CHEMISTRY, 1997, 40 (10) :1447-1454

[37] 5-alkyl-2-(alkylthio)-6-(2,6-dihalophenylmethyl)-3,4-dihydropyrimidin-4(3H)-ones: Novel potent and selective dihydro-alkoxy-benzyl-oxopyrimidine derivatives [J].

Mai, A ;

Artico, M ;

Sbardella, G ;

Massa, S ;

Novellino, E ;

Greco, G ;

Loi, AG ;

Tramontano, E ;

Marongiu, ME ;

La Colla, P .

JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (04) :619-627

[38] Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase [J].

Mai, A ;

Sbardella, G ;

Artico, M ;

Ragno, R ;

Massa, S ;

Novellino, E ;

Greco, G ;

Lavecchia, A ;

Musiu, C ;

La Colla, M ;

Murgioni, C ;

La Colla, P ;

Loddo, R .

JOURNAL OF MEDICINAL CHEMISTRY, 2001, 44 (16) :2544-2554

[39]

McGuigan C, 2003, ANTIVIR RES, V57, pA57

[40] Highly potent and selective inhibition of varicella-zoster virus by bicyclic furopyrimidine nucleosides bearing an aryl side chain [J].

McGuigan, C ;

Barucki, H ;

Blewett, S ;

Carangio, A ;

Erichsen, JT ;

Andrei, G ;

Snoeck, R ;

De Clercq, E ;

Balzarini, J .

JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (26) :4993-4997

← 1 2 3 4 5 6 →